Angels for Change (A4C) announces the pilot launch of Project GOLD (Generic Oncology Lifesaving Drugs), a new resiliency program that establishes an onshore buffer supply of six essential medications that are used to treat cancer. Project GOLD was created to offer physicians and patients stability of care during a shortage through emergency supply at leading distributors and manufacturers. A4C is participating with founding pilot members, pharmaceutical wholesalers Cencora and McKesson, and  pharmaceutical and medtech manufacturer Fresenius Kabi.

Angels for Change (A4C) announces its 2024 Change Maker of the Year Award , Lindsey Thomas, Senior Vice President of Marketing at Fresenius Kabi USA. Lindsey was recognized for her exceptional leadership, collaborative spirit, and unwavering commitment to patient care, particularly in addressing the critical  chemotherapy drug shortages during  2023 and 2024.

Angels for Change applauds Senator Kaine, Senator Cotton, Representative Spanberger, and Representative Smith for their bipartisan leadership in taking on the drug shortage crisis and advancing this vital work. We are proud to support the End Drug Shortages Act.

How Pharmaceutical Supply Chain Advancements are Meeting the Moment and Beyond panel at Milken Institute Future of Health Summit, moderated by Sarah Karlin-Smith from Citeline, with Panelists Laura Bray from Angels for Change, Shamiram Feinglass MD, MPH from Manatt, Phelps & Phillips, LLP, Kirk Kaminsky from McKesson and Vimala Raghavendran from US Pharmacopeia.

Angels for Change is proud to announce a significant milestone in Project PROTECT. Fagron Sterile Services US (FSS), a recipient of the 2023 Project PROTECT grant and a leader 503B outsourcing, has completed the Preparation and Protective phases for preservative-free Dextrose 70% injection solution. The significance of this achievement is highlighted by the recent flooding at Baxter's North Cove manufacturing site due to Hurricane Helene, which prompted the U.S. Food and Drug Administration to include Dextrose on its drug shortage list as of October 12, 2024. The strategic preparations made through Project PROTECT, Dextrose will remain accessible to vulnerable patients, especially PICU and NICU babies, amid anticipated supply chain disruptions.